Rockefeller University Press

Table I.

Changes in Sec61 complex configuration during the translocation cycle

Donor	Acceptor	Untreated	Puromycin	Pactamycin
Sec61α	Sec61α	38.3 ± 4.4	33.6 ± 7.2^{^a}	35.5 ± 5.1^{^a}
Sec61α	Sec61β	26.4 ± 2.1	27.9 ± 2.7^{^a}	28.0 ± 2.1^{^a}
Sec61β	Sec61α	41.8 ± 3.1	46.1 ± 2.8^{^a}	46.8 ± 3.0^{^a}
Sec61β	Sec61β	21.4 ± 3.6	24.8 ± 6.1^{^a}	23.9 ± 2.5^{^a}

Donor	Acceptor	Untreated	Puromycin	Pactamycin
Sec61α	Sec61α	38.3 ± 4.4	33.6 ± 7.2^{^a}	35.5 ± 5.1^{^a}
Sec61α	Sec61β	26.4 ± 2.1	27.9 ± 2.7^{^a}	28.0 ± 2.1^{^a}
Sec61β	Sec61α	41.8 ± 3.1	46.1 ± 2.8^{^a}	46.8 ± 3.0^{^a}
Sec61β	Sec61β	21.4 ± 3.6	24.8 ± 6.1^{^a}	23.9 ± 2.5^{^a}

Treatment is significant (P ≤ 0.01) compared with untreated cells using t test.

FRET efficiencies (mean ± SD; n = 40) for the indicated donor–acceptor antibody pairs were measured on cells that were either left untreated or pre-treated for 15 min with 1 mM puromycin or 0.2 μM pactamycin. Each value is the mean of measurements collected from four separate experiments performed on multiple days.

View Large

This Feature Is Available To Subscribers Only